B+
Bull case
25%
Probability
Target price
$27.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
AKTS
Aktis OncologyDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Two AKY-2519 Phase 1b trials are now underway, while AKY-1189 has a Q1 2027 preliminary-data target. Aktis reported $517.3 million in cash, equivalents and marketable securities at June 30 and expected its operating plan to be funded into 2029.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -4.1.
What can break
AKY-1189 and AKY-2519 have not demonstrated therapeutic efficacy in the cited early-stage updates; preliminary readouts may be delayed or disappointing. [#SEC-8K-2026-08-13]
Momentum
4
Value
46
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $16.00 · Bull $27.00 · Bear $8.00Analysis 2026-10-16; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $36.00
Why
Momentum4 · Δ7d +0.1
Value46 · Δ7d +0.0
Sentiment62 · Δ7d -4.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta -4.1.
Contradictions & invalidation
- • AKY-1189 and AKY-2519 have not demonstrated therapeutic efficacy in the cited early-stage updates; preliminary readouts may be delayed or disappointing. [#SEC-8K-2026-08-13]
- • Rising R&D expenditure and clinical-supply execution could shorten the projected runway into 2029 if spending exceeds the company plan. [#SEC-8K-2026-08-13]
- • The programs remain early-stage.
Catalyst clock
2026-12-31
Internal clinical-supply facility
Lead driver: Sentiment · See AI snapshot
Momentum
4
8% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.4
Value
46
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
0.0
Sentiment
62
45% active weight
Current posture
7d trendSoftening
Δ7d
-4.1
Δ21d
-22.6
Why this grade
Composite grade D. Momentum 3.8 / Value 46.5 / Sentiment 62.3
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-16. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-16 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$874.9M
Beta
-
Shares Out
55.62M
P/E (TTM) · Derived
-13.2
P/S (TTM)
-
P/FCF (TTM)
-
Rev YoY
+111.4%
EPS YoY
+33.6%
Gross Margin
-
Op Margin
-
Net Debt
-$215.24M
Current Ratio
16.33
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data